Share Price and Basic Stock Data
Last Updated: December 30, 2025, 8:01 pm
| PEG Ratio | 4.31 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Anuh Pharma Ltd operates in the pharmaceuticals sector, focusing on the manufacturing and distribution of pharmaceutical products. The company’s stock price stood at ₹80.0, with a market capitalization of ₹806 Cr. In terms of revenue, Anuh Pharma reported sales of ₹527 Cr for the fiscal year ending March 2023, reflecting a steady increase from ₹487 Cr in March 2022. Sales for the trailing twelve months (TTM) reached ₹730 Cr, indicating a robust growth trajectory. Quarterly sales data illustrates fluctuations, with the highest quarterly sales of ₹172.10 Cr recorded in December 2023 and a notable dip to ₹137.91 Cr in June 2024. Despite these fluctuations, the overall trend indicates a positive revenue growth, suggesting effective market positioning and product demand.
Profitability and Efficiency Metrics
Profitability metrics for Anuh Pharma demonstrate a solid operational performance. The company reported a net profit of ₹39 Cr for FY 2025, with an earnings per share (EPS) of ₹9.45. The operating profit margin (OPM) stood at 6.39%, while the return on equity (ROE) was recorded at 13.4%. These figures are indicative of efficient cost management and operational effectiveness. The interest coverage ratio (ICR) was exceptionally high at 113.62x, reflecting robust earnings relative to interest obligations, which is significantly above typical sector norms. However, the OPM has shown a declining trend from 11.67% in September 2022 to 6.39% in September 2025, highlighting potential challenges in maintaining profitability amidst rising costs or pricing pressures.
Balance Sheet Strength and Financial Ratios
Anuh Pharma’s balance sheet exhibits considerable strength, characterized by zero borrowings, which underscores a solid capital structure devoid of debt liabilities. The company’s reserves stood at ₹277 Cr, contributing to a healthy equity base. The price-to-book value (P/BV) ratio was reported at 2.29x, indicating that the stock is trading at a premium compared to its book value, which stood at ₹65.06 per share as of March 2025. The current ratio of 2.11x suggests strong liquidity, allowing the company to meet short-term obligations comfortably. However, the decline in the return on capital employed (ROCE) to 17% in FY 2025 from 26.84% in FY 2024 may raise concerns about the efficiency of capital utilization and future growth prospects.
Shareholding Pattern and Investor Confidence
The shareholding structure of Anuh Pharma reveals a strong promoter holding of 71.81%, indicating significant management control and alignment with shareholder interests. The public holding stood at 28.19%, with foreign institutional investors (FIIs) and domestic institutional investors (DIIs) holding negligible stakes, suggesting limited institutional interest. The number of shareholders increased to 28,250 by September 2025, reflecting growing retail interest. However, the gradual decline in promoter holding from 70.59% in December 2022 to 69.91% in March 2025 raises questions about potential dilution of control. Investor confidence appears robust given the high market cap and consistent profitability, but the lack of institutional backing may pose risks regarding stock liquidity and valuation stability.
Outlook, Risks, and Final Insight
Looking ahead, Anuh Pharma’s growth prospects appear promising, fueled by increasing sales and a solid balance sheet. However, several risks could impact its trajectory. The declining OPM and ROCE suggest that the company may face challenges in sustaining profitability as operational costs rise or market competition intensifies. Additionally, the absence of debt provides a cushion, but it may also limit leverage for growth opportunities. On the positive side, the strong promoter holding and high interest coverage ratio indicate resilience in financial health. If operational efficiencies can be improved, and market conditions remain favorable, Anuh Pharma could capitalize on its growth momentum. Conversely, any adverse regulatory changes or market disruptions could pose significant risks to its performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100.0 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,735 Cr. | 436 | 479/192 | 98.0 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.7 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.1 Cr. | 35.6 | 36.4/17.0 | 124 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,996.96 Cr | 1,139.22 | 52.85 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 115.07 | 138.73 | 157.31 | 161.48 | 149.53 | 172.10 | 163.89 | 137.91 | 165.95 | 159.51 | 198.14 | 186.48 | 185.88 |
| Expenses | 101.64 | 126.30 | 143.08 | 147.51 | 131.57 | 148.11 | 144.67 | 127.34 | 149.07 | 144.72 | 179.47 | 176.19 | 174.00 |
| Operating Profit | 13.43 | 12.43 | 14.23 | 13.97 | 17.96 | 23.99 | 19.22 | 10.57 | 16.88 | 14.79 | 18.67 | 10.29 | 11.88 |
| OPM % | 11.67% | 8.96% | 9.05% | 8.65% | 12.01% | 13.94% | 11.73% | 7.66% | 10.17% | 9.27% | 9.42% | 5.52% | 6.39% |
| Other Income | 2.01 | 2.11 | 1.04 | 3.47 | 2.15 | 3.66 | 2.82 | 3.72 | 3.40 | 0.94 | 1.40 | 3.39 | 0.98 |
| Interest | 0.11 | 0.03 | 0.02 | 0.02 | 0.09 | 0.14 | 0.10 | 0.14 | 0.16 | 0.28 | 0.03 | 0.21 | 0.08 |
| Depreciation | 2.44 | 2.43 | 2.41 | 2.01 | 2.15 | 2.20 | 2.23 | 1.88 | 1.92 | 2.18 | 2.76 | 2.52 | 2.86 |
| Profit before tax | 12.89 | 12.08 | 12.84 | 15.41 | 17.87 | 25.31 | 19.71 | 12.27 | 18.20 | 13.27 | 17.28 | 10.95 | 9.92 |
| Tax % | 23.04% | 22.93% | 25.08% | 23.75% | 22.61% | 24.46% | 22.12% | 22.49% | 17.31% | 22.00% | 27.95% | 24.20% | 23.29% |
| Net Profit | 9.92 | 9.31 | 9.62 | 11.75 | 13.83 | 19.11 | 15.36 | 9.51 | 15.04 | 10.34 | 12.46 | 8.30 | 7.61 |
| EPS in Rs | 0.99 | 0.93 | 0.96 | 1.17 | 1.38 | 1.91 | 1.53 | 0.95 | 1.50 | 1.03 | 1.24 | 0.83 | 0.76 |
Last Updated: December 28, 2025, 3:32 am
Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 185.88 Cr.. The value appears to be declining and may need further review. It has decreased from 186.48 Cr. (Jun 2025) to 185.88 Cr., marking a decrease of 0.60 Cr..
- For Expenses, as of Sep 2025, the value is 174.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 176.19 Cr. (Jun 2025) to 174.00 Cr., marking a decrease of 2.19 Cr..
- For Operating Profit, as of Sep 2025, the value is 11.88 Cr.. The value appears strong and on an upward trend. It has increased from 10.29 Cr. (Jun 2025) to 11.88 Cr., marking an increase of 1.59 Cr..
- For OPM %, as of Sep 2025, the value is 6.39%. The value appears strong and on an upward trend. It has increased from 5.52% (Jun 2025) to 6.39%, marking an increase of 0.87%.
- For Other Income, as of Sep 2025, the value is 0.98 Cr.. The value appears to be declining and may need further review. It has decreased from 3.39 Cr. (Jun 2025) to 0.98 Cr., marking a decrease of 2.41 Cr..
- For Interest, as of Sep 2025, the value is 0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.21 Cr. (Jun 2025) to 0.08 Cr., marking a decrease of 0.13 Cr..
- For Depreciation, as of Sep 2025, the value is 2.86 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.52 Cr. (Jun 2025) to 2.86 Cr., marking an increase of 0.34 Cr..
- For Profit before tax, as of Sep 2025, the value is 9.92 Cr.. The value appears to be declining and may need further review. It has decreased from 10.95 Cr. (Jun 2025) to 9.92 Cr., marking a decrease of 1.03 Cr..
- For Tax %, as of Sep 2025, the value is 23.29%. The value appears to be improving (decreasing) as expected. It has decreased from 24.20% (Jun 2025) to 23.29%, marking a decrease of 0.91%.
- For Net Profit, as of Sep 2025, the value is 7.61 Cr.. The value appears to be declining and may need further review. It has decreased from 8.30 Cr. (Jun 2025) to 7.61 Cr., marking a decrease of 0.69 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.76. The value appears to be declining and may need further review. It has decreased from 0.83 (Jun 2025) to 0.76, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:13 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 730 |
| Expenses | 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 674 |
| Operating Profit | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 56 |
| OPM % | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% |
| Other Income | 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 7 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 10 |
| Profit before tax | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 51 |
| Tax % | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | |
| Net Profit | 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 39 |
| EPS in Rs | 1.76 | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 3.86 |
| Dividend Payout % | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.22% | 18.18% | -23.08% | -15.00% | 35.29% | -39.13% | 100.00% | 10.71% | 16.13% | 66.67% | -21.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -4.04% | -41.26% | 8.08% | 50.29% | -74.42% | 139.13% | -89.29% | 5.41% | 50.54% | -88.33% |
Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 26% |
| 3 Years: | 13% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -3% |
| 3 Years: | 21% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 2:21 pm
Balance Sheet
Last Updated: December 4, 2025, 2:22 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 82 | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 277 |
| Borrowings | 0 | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 |
| Other Liabilities | 77 | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 182 |
| Total Liabilities | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 509 |
| Fixed Assets | 12 | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 61 |
| CWIP | 0 | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 27 | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 71 |
| Other Assets | 124 | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 376 |
| Total Assets | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 509 |
Below is a detailed analysis of the balance sheet data for Anuh Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 277.00 Cr.. The value appears to be declining and may need further review. It has decreased from 301.00 Cr. (Mar 2025) to 277.00 Cr., marking a decrease of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 11.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 11.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 182.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 170.00 Cr. (Mar 2025) to 182.00 Cr., marking an increase of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 507.00 Cr. (Mar 2025) to 509.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 61.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 71.00 Cr.. The value appears to be declining and may need further review. It has decreased from 106.00 Cr. (Mar 2025) to 71.00 Cr., marking a decrease of 35.00 Cr..
- For Other Assets, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 342.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 34.00 Cr..
- For Total Assets, as of Sep 2025, the value is 509.00 Cr.. The value appears strong and on an upward trend. It has increased from 507.00 Cr. (Mar 2025) to 509.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (277.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 24.00 | 31.00 | 36.00 | 23.00 | 16.00 | 26.00 | -22.00 | 31.00 | 43.00 | 51.00 | 73.00 | 51.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 |
| Inventory Days | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 |
| Days Payable | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 |
| Cash Conversion Cycle | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 |
| Working Capital Days | 42 | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 |
| ROCE % | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| Diluted EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| Cash EPS (Rs.) | 11.19 | 13.70 | 9.15 | 8.48 | 8.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 |
| Dividend / Share (Rs.) | 1.50 | 2.50 | 2.00 | 1.75 | 1.50 |
| Revenue From Operations / Share (Rs.) | 132.01 | 129.11 | 105.26 | 97.11 | 86.20 |
| PBDIT / Share (Rs.) | 14.04 | 17.41 | 11.45 | 10.39 | 11.00 |
| PBIT / Share (Rs.) | 12.30 | 15.70 | 9.52 | 8.00 | 7.99 |
| PBT / Share (Rs.) | 12.17 | 15.63 | 9.47 | 7.81 | 7.69 |
| Net Profit / Share (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| PBDIT Margin (%) | 10.63 | 13.48 | 10.87 | 10.69 | 12.76 |
| PBIT Margin (%) | 9.31 | 12.15 | 9.04 | 8.23 | 9.27 |
| PBT Margin (%) | 9.22 | 12.10 | 8.99 | 8.03 | 8.92 |
| Net Profit Margin (%) | 7.15 | 9.28 | 6.85 | 6.27 | 6.58 |
| Return on Networth / Equity (%) | 14.52 | 20.62 | 14.99 | 14.29 | 14.91 |
| Return on Capital Employeed (%) | 18.78 | 26.84 | 19.57 | 18.53 | 20.73 |
| Return On Assets (%) | 9.34 | 13.47 | 8.93 | 8.80 | 8.54 |
| Total Debt / Equity (X) | 0.03 | 0.01 | 0.00 | 0.01 | 0.07 |
| Asset Turnover Ratio (%) | 1.39 | 1.52 | 1.40 | 1.43 | 1.31 |
| Current Ratio (X) | 2.11 | 2.20 | 1.91 | 1.98 | 1.70 |
| Quick Ratio (X) | 1.69 | 1.71 | 1.46 | 1.37 | 1.12 |
| Inventory Turnover Ratio (X) | 8.83 | 8.74 | 4.94 | 4.36 | 4.53 |
| Dividend Payout Ratio (NP) (%) | 26.45 | 16.68 | 24.23 | 24.59 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 22.33 | 14.60 | 19.11 | 17.67 | 0.00 |
| Earning Retention Ratio (%) | 73.55 | 83.32 | 75.77 | 75.41 | 0.00 |
| Cash Earning Retention Ratio (%) | 77.67 | 85.40 | 80.89 | 82.33 | 0.00 |
| Interest Coverage Ratio (X) | 113.62 | 246.74 | 262.77 | 54.16 | 36.88 |
| Interest Coverage Ratio (Post Tax) (X) | 77.46 | 170.85 | 166.66 | 32.80 | 20.03 |
| Enterprise Value (Cr.) | 736.68 | 1223.09 | 392.34 | 417.88 | 446.02 |
| EV / Net Operating Revenue (X) | 1.11 | 1.89 | 0.74 | 0.85 | 1.03 |
| EV / EBITDA (X) | 10.47 | 14.02 | 6.84 | 8.03 | 8.09 |
| MarketCap / Net Operating Revenue (X) | 1.13 | 1.90 | 0.75 | 0.88 | 1.05 |
| Retention Ratios (%) | 73.54 | 83.31 | 75.76 | 75.40 | 0.00 |
| Price / BV (X) | 2.29 | 4.23 | 1.65 | 2.01 | 2.37 |
| Price / Net Operating Revenue (X) | 1.13 | 1.90 | 0.75 | 0.88 | 1.05 |
| EarningsYield | 0.06 | 0.04 | 0.09 | 0.07 | 0.06 |
After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.19. This value is within the healthy range. It has decreased from 13.70 (Mar 24) to 11.19, marking a decrease of 2.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 24) to 1.50, marking a decrease of 1.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 132.01. It has increased from 129.11 (Mar 24) to 132.01, marking an increase of 2.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.04. This value is within the healthy range. It has decreased from 17.41 (Mar 24) to 14.04, marking a decrease of 3.37.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.30. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.30, marking a decrease of 3.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has decreased from 15.63 (Mar 24) to 12.17, marking a decrease of 3.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For PBDIT Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has decreased from 13.48 (Mar 24) to 10.63, marking a decrease of 2.85.
- For PBIT Margin (%), as of Mar 25, the value is 9.31. This value is below the healthy minimum of 10. It has decreased from 12.15 (Mar 24) to 9.31, marking a decrease of 2.84.
- For PBT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 12.10 (Mar 24) to 9.22, marking a decrease of 2.88.
- For Net Profit Margin (%), as of Mar 25, the value is 7.15. This value is within the healthy range. It has decreased from 9.28 (Mar 24) to 7.15, marking a decrease of 2.13.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.52. This value is below the healthy minimum of 15. It has decreased from 20.62 (Mar 24) to 14.52, marking a decrease of 6.10.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has decreased from 26.84 (Mar 24) to 18.78, marking a decrease of 8.06.
- For Return On Assets (%), as of Mar 25, the value is 9.34. This value is within the healthy range. It has decreased from 13.47 (Mar 24) to 9.34, marking a decrease of 4.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.39. It has decreased from 1.52 (Mar 24) to 1.39, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.11, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.69, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.83. This value exceeds the healthy maximum of 8. It has increased from 8.74 (Mar 24) to 8.83, marking an increase of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.45. This value is within the healthy range. It has increased from 16.68 (Mar 24) to 26.45, marking an increase of 9.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 22.33. This value is within the healthy range. It has increased from 14.60 (Mar 24) to 22.33, marking an increase of 7.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.55. This value exceeds the healthy maximum of 70. It has decreased from 83.32 (Mar 24) to 73.55, marking a decrease of 9.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 77.67. This value exceeds the healthy maximum of 70. It has decreased from 85.40 (Mar 24) to 77.67, marking a decrease of 7.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 113.62. This value is within the healthy range. It has decreased from 246.74 (Mar 24) to 113.62, marking a decrease of 133.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 77.46. This value is within the healthy range. It has decreased from 170.85 (Mar 24) to 77.46, marking a decrease of 93.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is 736.68. It has decreased from 1,223.09 (Mar 24) to 736.68, marking a decrease of 486.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.11, marking a decrease of 0.78.
- For EV / EBITDA (X), as of Mar 25, the value is 10.47. This value is within the healthy range. It has decreased from 14.02 (Mar 24) to 10.47, marking a decrease of 3.55.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
- For Retention Ratios (%), as of Mar 25, the value is 73.54. This value exceeds the healthy maximum of 70. It has decreased from 83.31 (Mar 24) to 73.54, marking a decrease of 9.77.
- For Price / BV (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.23 (Mar 24) to 2.29, marking a decrease of 1.94.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
- Net Profit Margin: 7.15%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.78% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.52% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 77.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.8 (Industry average Stock P/E: 52.85)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.15%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3-A, Shivsagar Estate, Mumbai Maharashtra 400018 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Todarwal | Chairman & Non-Exe.Director |
| Mr. Bipin N Shah | Vice Chairman & Non Exe.Dire |
| Mr. Ritesh B Shah | Joint Managing Director |
| Mr. Vivek B Shah | Joint Managing Director |
| Mr. Bharat Shah | Non Executive Director |
| Mr. Samir Shah | Non Executive Director |
| Mr. Gaurav S Shah | Non Executive Director |
| Mr. Ketan Shah | Non Executive Director |
| Dr.(Ms.) Mita Dixit | Independent Director |
| Mr. Siddharth J Shah | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
| Mr. Harmanbhai Patel | Independent Director |
FAQ
What is the intrinsic value of Anuh Pharma Ltd?
Anuh Pharma Ltd's intrinsic value (as of 30 December 2025) is 74.05 which is 7.44% lower the current market price of 80.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 806 Cr. market cap, FY2025-2026 high/low of 117/74.0, reserves of ₹277 Cr, and liabilities of 509 Cr.
What is the Market Cap of Anuh Pharma Ltd?
The Market Cap of Anuh Pharma Ltd is 806 Cr..
What is the current Stock Price of Anuh Pharma Ltd as on 30 December 2025?
The current stock price of Anuh Pharma Ltd as on 30 December 2025 is 80.0.
What is the High / Low of Anuh Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Anuh Pharma Ltd stocks is 117/74.0.
What is the Stock P/E of Anuh Pharma Ltd?
The Stock P/E of Anuh Pharma Ltd is 20.8.
What is the Book Value of Anuh Pharma Ltd?
The Book Value of Anuh Pharma Ltd is 32.6.
What is the Dividend Yield of Anuh Pharma Ltd?
The Dividend Yield of Anuh Pharma Ltd is 1.87 %.
What is the ROCE of Anuh Pharma Ltd?
The ROCE of Anuh Pharma Ltd is 17.2 %.
What is the ROE of Anuh Pharma Ltd?
The ROE of Anuh Pharma Ltd is 13.4 %.
What is the Face Value of Anuh Pharma Ltd?
The Face Value of Anuh Pharma Ltd is 5.00.